Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Raúl Díaz-Molina[1]

1 Autonomous University of Baja California

It is a very good work and sufficiently extensive.

The introduction is very complete and includes the very general objective and results of the work.

The methodology is very well described.

Some observations are the following:

1. In the introduction the abbreviation EMA is mentioned, but the authors do not indicate what that abbreviation means.

2. Some materials used do not bear their trademark.

3. Table I must indicate its title in the higher art and at the bottom of the table the meanings of the results presented must be indicated (IC50 or %?).

4. Table II has the error of being considered Table I. At the foot of this Table II the meaning of the letter "a" must be indicated or defined.